Intra-Cellular Therapies Inc. Stock News

Intra-Cellular Therapies (NASDAQ:ITCI) had its target price hoisted by research analysts at SVB Leerink from $45.00 to $50.00 in a report released on Monday, Price Targets.com reports. The brokerage currently has an outperform rating on the biopharmaceutical companys stock. SVB Leerinks price target indicates a potential upside of 3.73% from the stocks previous close. A []

Intra-Cellular Therapies (NASDAQ:ITCI) had its target price boosted by investment analysts at Needham & Company LLC from $55.00 to $59.00 in a research note issued on Monday, Price Targets.com reports. The firm currently has a buy rating on the biopharmaceutical companys stock. Needham & Company LLCs price objective indicates a potential upside of 22.41% from []

Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) hit a new 52-week high during trading on Monday after Royal Bank of Canada raised their price target on the stock from $50.00 to $55.00. Royal Bank of Canada currently has an outperform rating on the stock. Intra-Cellular Therapies traded as high as $47.43 and last traded at $46.04, []

Intra-Cellular Therapies (NASDAQ:ITCI) was downgraded by Zacks Investment Research from a hold rating to a sell rating in a research note issued on Tuesday, Zacks.com reports. According to Zacks, Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous []

Companies in the news are: ITCI, VRS, CANF, FSM

PALM BEACH, Fla. , Dec. 21, 2021 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - Breast cancer is cancer that develops in the breast tissue. Breast cancer signs include the formation of a lump in the breast and red patches on the skin. Obesity, lack of physical activity, excessive radiation exposure, and alcohol use are all risk factors for breast cancer. Breast cancer is more prevalent in developed countries than it is in developing countries. Post diagnosis, cancer therapy requires different procedures depending upon the form and severity of cancer. The cancer care market is increasing at a substantial pace due to the rise in the occurrence of cancer cases, growing knowledge among people about different stages, and availability of treatment of cancer. Breast cancer treatment relies on different factors, such as breast cancer origin, tumor size, and breast cancer phase, and cancer grade. Operations, radiation therapy, chemotherapy, hormone therapy, targeted therapy, and bone-led therapy are some of the most popular approaches used in the management of breast cancer.

Intra-Cellular Therapies received FDA approval of CAPLYTA for the treatment of adults with bipolar depression. Total revenues of CAPLYTA in Q3 2021 for treatment of adults with Schizophrenia surged by

The new week didn't bring an end to heightened volatility.

CAPLYTA is the only FDA-approved treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults as monotherapy and as adjunctive therapy with lithium or valp

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Merck Announces Publication Of Positive Data From Late-Stage Study Of Oral COVID-19 Antiviral Treatmen

Wall Street analysts expect Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) to report sales of $24.02 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Intra-Cellular Therapies earnings. The highest sales estimate is $24.50 million and the lowest is $23.05 million. Intra-Cellular Therapies reported sales of $12.45 million in the same []

Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into risky bets amid the broader market rebound. Multiple conference presentations

Jaffetilchin Investment Partners LLC lowered its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 51.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 43,780 shares of the biopharmaceutical companys stock after selling 47,158 shares during the period. Jaffetilchin Investment Partners []

Intra-Cellular Therapies Inc. (NASDAQ:ITCI) price on Friday, December 10, fall -5.41% below its previous days close as a downside momentum from buyers pushed the stocks value to $35.67. A look at the stocks price movement, the close in the last trading session was $37.71, moving within a range at $34.75 and $37.98. The beta value Intra-Cellular Therapies Inc. (ITCI) Is Worth Looking Despite A Loss Of -31.85% From High Read More »

Related Stocks: AMGN , NVAX , ITCI , SRPT , BGNE , GH , ALKS , AZN , CRBU , CRL , RLYB , BHVN , ALLK , BPMC , BBIO , IOVA , DCPH , REPL ,